NCT02353143

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia

The Sponsor accepted the iDSMB recommendation to terminate the study due to evidence of unpredictable liver toxicity and meaningful target engagement not translating into any clinical objective response.